PGAM1 Inhibitors

PGAM1 inhibitors encompass a range of compounds that target either the enzyme directly or modulate associated metabolic pathways, particularly glycolysis and gluconeogenesis. PGAM1 is a key enzyme in these pathways, playing a vital role in energy production and metabolic flux within cells. The direct inhibitors of PGAM1, such as MJE3, Shikonin, and PGMI-004A, work by binding to the active site of the enzyme, effectively blocking its catalytic activity. This blockade results in the disruption of the glycolytic pathway, a critical process in energy production, especially in rapidly proliferating cells, like cancer cells.

MJE3, as a specific PGAM1 inhibitor, provides a model for understanding the direct inhibition mechanism. By occupying the active site of PGAM1, MJE3 prevents the conversion of 3-phosphoglycerate to 2-phosphoglycerate, thus impacting the glycolytic flow. Shikonin and PGMI-004A follow a similar mode of action, directly targeting PGAM1 and offering valuable insights into the enzyme's role in cellular metabolism. The indirect inhibitors, such as Oxamic acid, 3-Bromopyruvate, Lonidamine, Dichloroacetate, and WZB117, target other enzymes or processes in the glycolytic pathway or related metabolic pathways. For example, Oxamic acid and Galloflavin inhibit lactate dehydrogenase, impacting the final steps of glycolysis and consequently influencing PGAM1 activity. Lonidamine and Dichloroacetate modulate enzymes upstream of PGAM1, thereby altering the availability of substrates and intermediates necessary for PGAM1's action. WZB117 and 2-Deoxy-D-glucose inhibit glucose uptake and utilization, respectively, impacting glycolytic flux and indirectly affecting PGAM1 activity.